Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Endocr Relat Cancer. 2017 Feb 1;24(4):R81–R97. doi: 10.1530/ERC-16-0482

Figure 3.

Figure 3

Current approaches using therapeutic siRNA nanoparticles in the treatment of TNBCs. A) siRNA nanoparticles delivering siRNA against FoxM1, CDK11/CK2, and CDK1 are demonstrated to significantly reduce primary tumor burden. B) siRNA nanoparticles silencing Twist and β3 integrin inhibits EMT. Nanoparticles delivering β3 integrin siRNA also reduce primary tumor burden, primary tumor recurrence, and metastasis in MDA-MB-231 mouse xenograft models. C) Complex nanoparticles utilize siRNAs to improve chemotherapeutic efficacy.